Drug Trial Radar · NCT07944105
SPARK UPS/MFS: Study Of BET Inhibition With ZEN003694 To Potentiate Anti-Tumor Responses With Radiotherapy To Kickstart Abscopal Effect In Metastatic Undifferentiated Pleomorphic Sarcoma (UPS) And Myxofibrosarcoma (MFS).
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
57
Planned (sponsor's estimate)
Start
May 31, 2027
Primary completion
Dec 31, 2030
Study completion Dec 31, 2032
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-center, Phase 1/2 clinical trial evaluating the safety, tolerability, RP2D, and preliminary efficacy of ZEN003694 in combination with RT in patients with metastatic UPS and MFS who have completed first- or second- line doxorubicin-based chemotherapy without disease progression.
Conditions
- Undifferentiated Pleomorphic Sarcoma
- Myxofibrosarcoma
Interventions
ZEN003694Drug
Given orally once daily
Radiation TherapyDrug
The radiation therapy is to be delivered using a linear accelerator or proton gantry.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Adverse Events (AEs)Time frame: Through study completion; an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UT MD Anderson
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.